Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03800134
Title A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Durvalumab + Gemcitabine

Carboplatin + Paclitaxel

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Carboplatin + Durvalumab + Pemetrexed Disodium

Carboplatin + Durvalumab + Paclitaxel

Cisplatin + Durvalumab + Pemetrexed Disodium

Cisplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.